Q-omics provides the consensus-scored RANBP20P profile across patient tissues and cancer cell-line models. RANBP20P expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, RANBP20P is differentially expressed in 8, with the highest sampling consensus in BLCA. Additionally, RANBP20P RNA expression shows 8,339 significant gene co-expression associations, with the highest sampling consensus in PAAD. Together, these results highlight KICH, BLCA, and PAAD as cancer lineages where RANBP20P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RANBP20P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RANBP20P survival associations across molecular data types. RANBP20P RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RANBP20P RNA expression–survival associations across cancer types. High RANBP20P expression shows unfavorable associations in KICH, CESC, ESCA, DLBC, STAD and ACC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for RANBP20P RNA expression.
This table summarizes RANBP20P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for RANBP20P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RANBP20P shows lower tumor expression in BRCA and higher tumor expression in BLCA, COAD, LUAD, KIRC and STAD. The BLCA box plot shows higher RANBP20P RNA expression in tumor versus normal tissue (log2 FC = +0.055, t-test p = .010).
This table shows molecular features associated with RANBP20P in patient tissues and cancer cell lines. In patient samples, RANBP20P shows the broadest associations at the RNA and protein expression levels, with PAAD recurring as the lineage with the largest associated feature set.
